Cyclosporine in rheumatoid arthritis: beyond experimentation.
The potential for combined therapy in rheumatoid arthritis is rapidly increasing considering the recent development of various new treatment modalities. However, an aggressive effort must be made to stage patients according to various clinical and immunological parameters. Only then can appropriate combined therapy be used effectively in this disease process. The development of such combined therapy could expand into other diseases such as scleroderma, systemic lupus erythematosus, and multiple sclerosis.
Yocum
D E
DE
Department of Rheumatology and Immunology, University of Arizona Arthritis Center, Tucson.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005544:Forecasting; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D013583:Synovial Membrane / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D016572:Cyclosporine; D008727:Methotrexate